Google profit

Pfizer will sell all of its patented drugs at not-for-profit prices in 45 low-income countries

Pfizer Inc will make all of its patented drugs, including COVID-19 treatment Paxlovid and breast cancer drug Ibrance, available at a non-profit price in 45 of the world’s poorest countries, the drugmaker announced on Wednesday. .

These countries lack good access to innovative treatments. According to the Bill & Melinda Gates Foundation, it may take another four to seven years for new treatments to become available in low-income countries, if they become available.

For the latest headlines, follow our Google News channel online or through the app.

Pfizer said its plan includes 23 proprietary, patented drugs and vaccines that treat infectious diseases, certain cancers, and rare and inflammatory diseases. In addition to Paxlovid and Ibrance, the list includes pneumonia vaccine Prevnar 13, rheumatoid arthritis drug Xeljanz, and cancer treatments Xalkori and Inlyta.

The Comirnaty COVID-19 vaccine developed with BioNTech SE was also on the list.

Managing director Albert Bourla said in an interview that all the drugs made available should be useful.

“But clearly the antiviral (Paxlovid) is going to be very important to them – if they need it they can get it immediately,” he said.

When Pfizer launches new drugs and vaccines, they will also be included in the drug portfolio at a not-for-profit price, he said.

The 27 low-income countries and 18 low-income countries included in what Pfizer calls “A Deal for a Healthier World” cover most of Africa and much of Southeast Asia. Five countries – Rwanda, Ghana, Malawi, Senegal and Uganda – have already pledged to join the deal, which was announced at the World Economic Forum in Davos.

Malawi’s President Lazarus Chakwera said in a statement that the deal will allow countries and the drugmaker to share “the burden of costs and tasks in the production and delivery of supplies that will save millions of lives.” .

Pfizer has been criticized for the way it has rolled out its COVID-19 vaccine, with some poorer countries waiting months for the first doses to arrive in wealthier countries.

Bourla said the new agreement was informed by the difficulties of this deployment, in particular the lack of health infrastructure in some countries which made it difficult to distribute the vaccine.

“Instead of washing our hands and saying, ‘I gave you the product, do what you want with it,’ we say, ‘We’ll give you the product and sit down with you to see how we can help organize a system that can use them,” Bourla said.

Read more:

Pfizer and UAE renew partnership to fight cancer incidence and raise public awareness